The Effectiveness analysis is one of the stages of pharmacoeconomic analysis (PA). It is used for criterion (indicator) selection, which could shot as accurately and fully as possible efficacy, safety and utility of studying health technology. Choosing the correct efficiency allows for the subsequent stages of PA to conduct a comprehensive assessment of the impact of technology on the overall burden of disease.
parameters), and the safety of drug is assessed as mortality level and/or the number of adverse effects.
However, the information presented in this form is not always enough for the decision-makers (especially, if they are not specialists in this nosology). Moreover, for informed decision-making they need the results of PA, which take into account delayed effects of medical technology (e.g., changes in life expectancy), while carrying out clinical trials are not always possible.
The best and most common way to overcome the mentioned difficulties is pharmacoeconomic modeling. Mathematical models allow to predict the targeted consequences of medical technologies use (including delayed ones) on the basis of available results of clinical trials, as well as data on dependencies of targeted consequences medical technology use from the values of the performance indicator that was used in a clinical study. The consequences medical technology use is usually expressed as indicators, showing the duration and/or quality of life.
During effectiveness analysis of medical technology, we need to find answers to such questions as: Which criterion of effectiveness is the most reliable and will meet the aims of the work? How to measure this criterion? In which situations you can use the selected criteria? What time period allows the selected criterion of efficiency to make predictions?
In general, effectiveness analysis of medical technology includes the following stages: search, analysis and interpretation of data presented in the results of clinical studies (Fig. 1) . As mentioned above, the outcome of this analysis will be the choice efficiency criterion.
Effectiveness criteria
Effectiveness criteria (effectiveness point) is an indicator that allows to numerically express the degree of potential benefit or harm from the use of medical technology. For example, the effectiveness criteria may be: hormones level in blood, tumor size, assessment of patients' health, assessment of patients' functional abilities, the life expectancy of the patient, etc.
In pharmacoeconomic analysis there are certain requirements to effectiveness criteria, namely, they must be reliable (to reflect the consequences arising from the medical technology use without bias), sensitive to possible changes in generally accepted and, if possible, should reflect remote in time results.
It was already noted, that there are the differences in approaches to effectiveness estimation and as a consequence the difference in the in-use effectiveness indicators in clinical and pharmacoeconomic studies. In English literature, there are three separate terms that denotes «effectiveness», but used in a different context:
• Efficacy -efficacy of medical technology in clinical trials;
• Effectiveness -effectiveness of medical technology in real practice; • Efficiency -effectiveness of medical technology in pharmacoeconomic studies.
By analogy with above-mentioned separation used in PA conducting, effectiveness criteria can also be divided into:
• Surrogate endpoints -indicators that reflect the direct and indirect clinical effects (change of biochemical parameters, reducing the number of hospitalizations and so on);
• Final endpoints -indicators that reflect changes in health indicators at patients level (mortality, survival, life expectancy, disability, quality of life, etc).
A detailed description of the characteristics of each group are presented in table 1 .
In general, the choice of effectiveness criteria (effectiveness points should be chosen accordance with the purposes of the study, characteristics of the analyzed population, characteristics of the disease (life-threatening or not), treatment features (palliative or therapeutic use), time and financial possibilities. Biomarker is an indicator that reflects the qualitative and quantitative characteristics of biological processes, pathological processes or various forms of pharmacological response that occurs after a medical intervention. As biomarkers can be used: biochemical parameters, enzyme-linked immunosorbent indicators, quantitative and qualitative data on the substances in body tissues, data on the size of the organs/tumors, etc. It should be noted that the biomarker is used as a quantitative measure of any disorder, but not the disorder itself.
Naturally, the development of any pathological process as well as any medical intervention, accompanied by the change of numerous indicators in the body. However, to ensure that the indicator could be used as biomarkers (effectiveness criterion) of medical technology, it must meet obtain the following requirements [4] :
• specificity -it is preferable that the marker is the individual feature of a particular pathological process and is not influenced by internal and external factors;
• usability -a simple and clear measurement technique, which eliminates the bias;
• validity -selected for the evaluation of medical technologies biomarkers should correlate with the clinical target points (for example, disability) or, better, with endpoints (for example, with the number of extended life years) to allow estimation and prediction of the results. However, there are biomarkers of unknown validity, the use of which is based on general agreements in the medical and scientific practice, and biomarkers with probable validity, i.e. not estimated earlier publicly;
The use of biomarkers is usually used in cases when the clinical findings are rare/deferred (slowly progressive disease, prolonged observation which is not justified/consuming; rare diseases) or when the analysis focuses on lifethreatening diseases for which there are no therapeutic alternatives. To date, there is no list of biomarkers that would be acknowledged as valid indicators of the effectiveness of medical intervention. Only a few biomarkers approved for use as performance criteria (for example, the level of glycosylated hemoglobin in diabetes mellitus).
Biomarkers are usually used in cases when the clinical findings are rare/ delayed (slowly progressive disease, prolonged observation which is not justified/consuming; rare diseases) or when the analysis focuses on lifethreatening diseases for which there are no therapeutic alternatives. To date, there is no list of biomarkers that would be acknowledged as valid indicators of the effectiveness of medical intervention. Only a few biomarkers are approved for use as effectiveness criteria (for example, the level of glycosylated hemoglobin in pat). The use of biomarkers as performance criteria may lead to difficulties in the decision-making process, because presented in this form, the benefits of the analyzed medical technology is not so obvious. Therefore, this criterion can be used to evaluate medical technologies, mainly experts in specific nosology (doctors, researchers).
Clinical point (intermediate clinical effect) is the outcome of a disease or medical intervention, expressed in the form of certain clinical conditions or phenomena. Effects of medical technologies application, presented in the form of such effectiveness criterion, have high relevance for public health specialists and physicians. From the point of view of PA clinical endpoint can be used for more accurate assessment of medical technology (compared with the estimate made on the basis of biomarkers), because they allow to take into account the additional burden of the healthcare system due to adverse drug events, various complications etc.
As previously noted, in PA surrogate points are typically used in the modeling process implications of medical technologies. This approach is based on the assumption that the data on the level of biological markers/ clinical endpoints, the change occurred as a result of medical intervention, allows to predict endpoints' changes (Fig. 2) . The existence of a reasonable relationship between the surrogate and the final endpoints is a necessary condition for the validity of this assumption. Depending on the source, the connection can have three levels of evidence:
Level 1 In general, the use of surrogate endpoints as the only effectiveness criteria for medical technologies during PA is usually a least-evil solution in case of data absence required to build the data model.
Final endpoints
Final endpoint is a measure of outcomes that is used in direct evaluation process of medical intervention. To estimate the value of final endpoints it is possible to undertake the clinical, epidemiological and others types of study, that could collect data for the direct effect of medical intervention on, for example, life expectancy. It should be noted, that due to the rather long duration of these studies, the long-term outcomes of medical technology are obtained. However, in pharmacoeconomic researches usually models gives the value of final endpoints.
Different types of final endpoints have different levels of importance during analysis and evaluation of medical technology. Endpoints that reflect survival/mortality are of higher importance due to lower rate of mistakes in measuring/calculation (compare to other types of final endpoints) and the goal of medical treatment (that is, life sustaining).
Final endpoints can be:
• Population-based final endpoints reflect the outcomes of medical intervention on a scale of population: disablement, morbidity, mortality etc.;
• Individual-based final endpoints reflect the outcomes of medical intervention on a scale of certain patient: life years gained (LYG), quality adjusted life years (QALY).
The latter two indicators are widely used in pharmacoeconomic analysis, especially in case of cost-effectiveness analysis.
Life years gained (LYG) reflect the impact of health care intervention in terms of its effect on mortality and life expectancy [34] . However, this type of endpoint does not take into account that health is more than just staying alive. Therefore, the indicator called quality adjusted life years (QALY) was made; it reflects the effect of medical technology on both mortality and quality of life.
Nevertheless, in some cases QALY does not reflect the clinical benefits of intervention (for example, the technology affects the symptoms, but not the disease).
Furthermore, quality of life is rather individual measure; it may vary within groups of patients and societies. Therefore, studies dedicated to estimation the quality of life should contain set of measurements.
Conclusion
Advanced analysis of effectiveness makes a solid basis for subsequent stages of pharmacoeconomic analysis. Through the fact that all endpoints have both positive and negative aspects, choosing of certain endpoint in the process of health technology assessment should be done individually. All sources of data on efficacy/effectiveness should be checked for common methods of evaluation, similar characteristics of cohorts, similar characteristics of environment. Besides, proper understanding of definitions of indicators in data sources is important (especially, if it is written on foreign language).
LYG (life years gained) and QALY gained (quality adjusted life years gained) are the most common types of endpoints in pharmacoeconomic analysis. In case of decision-making process, these indicators should be taken into account.
